UK-based Apollon Formularies has officially opened its new International Cancer and Chronic Pain Institute (ICCPI) based in Kingston, Jamaica.
Specialising in complementary and alternative medical treatments for cancer patients, the clinic will prescribe Apollon’s own medical cannabis products.
The company’s products have been shown in preclinical data to be effective at fighting prostate cancer. The company’s combined treatment of medical cannabis and medicinal mushrooms has also been found to be effective at killing HER2+ breast cancer cells.
The company has stated that it has now been experiencing demand from international patients who wish to be treated in Jamaica. Due to this it will be admitting its second UK patient in mid-February 2022.
CEO Apollon Formularies Jamaica, Paul Burke, commented: “Our International Cancer Institute is one of a kind and I am proud to see our hard work pay off.
“Following our remarkable 3D cell culture test results and the expansion of our production facility, this next step will help Apollon compete on a world class level whilst providing our patients with the treatment and expert care needed.”
The ICCPI will also provide the opportunity to gather invaluable patient data on the Company’s medical cannabis formulations, where physicians will shortly initiate clinical trials on Apollon’s proprietary medical cannabis products. These will be carried out through Apollon’s research and development license with oversight from the Ministry of Health and Wellness in Jamaica.
Hon. Dr. Norman Dunn MP, State Minister in the Ministry of Industry, Investment and Commerce, commented: “It is my great pleasure to be part of today’s landmark occasion for Apollon Formularies as you open Jamaica’s first International Cancer and Chronic Pain Institute which has been established to offer complimentary plant-based medicine and to carry on clinical trials on cancer treatment formulations.
“From all accounts, their formulations have undergone rigorous third-party testing from esteemed pharmaceutical testing labs. I want to congratulate in particular Dr Stephen Barnhill and Dr Dingel Spence, Paul Burke and the rest of the team here at Apollon Formularies for your vision, tenacity and entrepreneurial spirit.”
CEO of Apollon Formularies, Dr Stephen Barnhill, commented: “I am glad to see the progress we have made as a Company come to fruition in the official opening of this impressive Cancer Institute. The facility will provide us with the opportunity to admit patients and use our proprietary formulations to treat common cancers. I would like to take this opportunity to thank the team on the ground in Jamaica who has helped make this happen.”
Apollon is increasing activities in Jamaica recently, with the announcement of a number of new agreements with Jamaica’s Cannabis License Authority (CLA) licensed cultivators allowing access to cannabis flower. The agreements will see Apollon working closely with Jamaican cannabis farmers to ensure they are not left out of the regulated medical cannabis system.
[activecampaign form=31]
